All News

ACRmtg.jpg (keep)

EULAR 2024 – Day 3 Report

d Jack Cush, MD

EULAR treats its attendees to a wonderful lunch each day – Schnitzel, gnocchi, goulash at lunch after muffins and coffee in the morning. It's no wonder the meeting has been a lively one, well attended with a wealth of stimulating ideas, research and discussion. Here are a few of my favorite abstracts and presentations from today, day 3 in Vienna.

Read Article
Setting a standard for imaging reporting in patients with suspected axial spondyloarthritis is an important part of our efforts toward improving the early and accurate diagnosis of SpA: https://t.co/zYbcL1CaTP https://t.co/1jnBDBSDNv

Links:

Prof. Denis Poddubnyy DrPoddubnyy ( View Tweet)
NEW biomarkers in #MAS 1️⃣ IL-18 (available at some 🏥)⭐️ 2️⃣ S100A12 3️⃣ CXCL9/10 🚨When suspecting #MAS, don’t ignore the possibility of a monogenic disorder! 🎙️ Dr. Sophie Georgin-Lavialle 🇫🇷 #macrophage #EULAR2024 #genetics #rheumx https://t.co/Uot3JjrWs8

Links:

Artem Minalyan, MD, DABOM AMinalyan ( View Tweet)
DMOADs in #osteoarthritis at #EULAR2024: 1) Tonia Vincent: StepUp OA endotype SF proteomics —> endothelial to mesenchymal transition proteins. 2) Phil Conaghan: proregenerative (& degeneration slowing) therapies in pipeline. 3) @Larhumato: novel RCT designs & structure outcomes

Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)

POS0277: proof of concept: Prophlx with canakinumab x 1 dose rather than steroids/colch/NSAIDS when starting pegloticase with MTX in pts with active, refractory gout: 11 pts: #gout flares 0 (compared 54% in MIRROR-C), infusion rxn 0, no safety signal @rheumnow https://t.co/4qFnQTOuq0

Links:

TheDaoIndex KDAO2011 ( View Tweet)
Recommendation for management of fatigue in people with rheumatic disease. Considering fatigue as a surrogate for inflammation and changing medication accordingly is part of it. I will also add yearly blood work including: 1- VitD 2-HBA1c and LDl 3-TsH. https://t.co/3QvPqMxZSN

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Enjoyed the #PolymyalgiaRheumatica session at #EULAR2024? Make sure to download our first atlas imaging article, where @drceowen, @drdavidliew et al. characterise PMR using whole-body PET/CT 👀 ➡️ https://t.co/tbu0DgAFIS https://t.co/W06YbYyjRx

Links:

Rheumatology & Rheumatology Advances in Practice RheumJnl ( View Tweet)
Mapping the knee #osteoarthritis joint-nerve interactome — presented by @AM_Malf at #EULAR2024. Anatomical and molecular neuroplasticity occurs during OA onset + progression in the joint and DRG. Cool imaging of nerves and their activity with lightsheet microscopy in mice https://t.co/cre6LEVhle

Links:

Tuhina Neogi, MD, PhD Tuhina_Neogi ( View Tweet)
Maintenance of remission in GPA/MPA. RTX for 48 months sounds good to me. #EULAR2024 https://t.co/5YGwOHhCuX

Links:

Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Potential efficacy of JAK inhibitors in VEXAS syndrome #EULAR2024 NZ https://t.co/HziLUgo1gA

Links:

Annals of the Rheumatic Diseases ARD_BMJ ( View Tweet)
500+ pts AxSPA No difference in drug discontinuation between IL-17i, TNFi, IL23i over time Adjusted for CRP, co-medication w/ MTX + classic covariates IL-17i and IL-23i had experienced a higher number bDMARD failures #EULAR2024 POS0259 @RheumNow https://t.co/F3B6uXyAca

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Cohort from Netherlands 400+ PsA pts IR first bioDMARD 300+ switched TNFi->IL-17i, 99 cycled TNFi->TNFi 3year retention rates 12 mo 75% cyclers 80% swappers 24mo 60% cyclers 56% swappers No difference in treatment failure or DAS28 CRP #EULAR2024 @RheumNow POS0278 https://t.co/J8ONjVAFqG

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
What is the meaning of mechanical stress-induced sacroiliac BMO MRI after childbirth in healthy women? 5yrs follow up MRI study shows: -decrease in BMO -1/3 BMO @ 5-year follow-up -15% ASAS definition of sacroiliitis -No correlation w/ symptoms @RheumNow #EULAR24 OP0222

Aurelie Najm AurelieRheumo ( View Tweet)

Understudied neurological involvement 🧠 in RA in pts > 65 vs. matched HC -larger lateral cerebral ventricles -brain atrophy -shrinkage of thalamus + frontal cortical regions -association w/ clinical depression @RheumNow POS0148 #EULAR2024 https://t.co/2mV4qGyBtW

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
BARI reduces nociplastic pain, small cohort RA n=13 -wk 12 ACR FM score 14 vs 10.5 p=0.03 -fMRI data: reduction connectivity between DMN and posterior insula & between IPL & anterior/middle insular regions Directs mechanims yet to be investigated @RheumNow POS0310 #EULAR2024 https://t.co/jGgvS5qqV6

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Is RA always preceded by clinically suspect arthralgia? Cohort 650+ pts CSA = 83 pts no CSA = 616 pts Pts w/ no CSA: -older -more frequent acute onset of symptoms -higher SJC -increased CRP -less ACPA+ No sure how accounted for memory bias #EULAR2024 @RheumNow POS1030 https://t.co/dJeN41ax5P

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

EFFICACY AND SAFETY OUTCOMES OF TAK-279, A SELECTIVE ORAL TYROSINE KINASE 2 (TYK2) INHIBITOR, FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS - smells tastes & looks like a Tyk2 - acne signal? @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

EFFECTIVENESS & COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPA (TeleSpA-STUDY): PRAGMATIC MULTICENTRE RVT cost effective but no one will ever be examined again especially for pathology outside joints! @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

FAPI PET/CT entheseal & synovial fibroblast activation predicts PsA in high risk PsO better than MUS @RheumNow #EULAR2024 https://t.co/uqmEvMg9WN

Links:

Peter Nash drpnash ( View Tweet)
×